论文部分内容阅读
目的:研究β2肾上腺素受体(ADR2)基因多态性和美托洛尔引起的血脂代谢紊乱的相关性。方法:美托洛尔100 mg.d-1单药治疗高血压患者,测量治疗前后血甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)浓度,分析TG/HDL-C比值的变化;并利用测序及PCR-RFLP方法进行基因多态性分析。结果:治疗后TG浓度和TG/HDL-C比值明显升高;携带ADR2的Arg16Arg基因型患者治疗前后血TG浓度和TG/HDL-C比值的差值明显小于Arg16Gly或Gly16Gly者。结论:ADR2的Arg16Gly多态性有可能是美托洛尔治疗后TG/HDL-C比值变化的标记物。
Objective: To investigate the association between β2-adrenergic receptor (ADR2) gene polymorphism and metoprolol-induced dyslipidemia. Metoprolol 100 mg.d-1 monotherapy in patients with hypertension, before and after treatment measured triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipids (HDL-C) were measured to analyze the changes of TG / HDL-C ratio. The gene polymorphism was analyzed by sequencing and PCR-RFLP. Results: The TG and HDL-C ratios were significantly increased after treatment. The difference of TG and HDL-C ratio between patients with and without Arg16Arg genotype before ADR2 was significantly lower than those with Arg16Gly or Gly16Gly. Conclusion: The Arg16Gly polymorphism of ADR2 may be a marker of the change of TG / HDL-C ratio after metoprolol treatment.